pralsetinib
blueprint medicines,roche
['nsclc', 'pralsetinib', 'sclc', ' arrow']
updated data from the phase 1/2 arrow study of pralsetinib in pts with advanced ret fusion+ #nsclc. 80% orr in 1l (post eligibility revision n = 69). only 10% of patients discontinued pralsetinib due to traes #esmo22 
MD, PhD, Prof of Respiratory Medicine, Thoracic Oncology Specialist @CHUdeToulouse, @IUCTOncopoleICR; Researcher, INSERM @crctoncopole #LCSM ????? ?? ??